TScan Therapeutics, Inc.

NasdaqGM:TCRX Lagerbericht

Marktkapitalisierung: US$262.2m

TScan Therapeutics Management

Management Kriterienprüfungen 0/4

TScan Therapeutics' CEO is Gavin MacBeath, appointed in Mar 2023, has a tenure of 1.67 years. total yearly compensation is $3.20M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.094% of the company’s shares, worth $246.36K. The average tenure of the management team and the board of directors is 0.9 years and 1.6 years respectively.

Wichtige Informationen

Gavin MacBeath

Geschäftsführender

US$3.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts17.1%
Amtszeit als Geschäftsführer1.7yrs
Eigentum des Geschäftsführers0.09%
Durchschnittliche Amtszeit des Managementsless than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder1.6yrs

Jüngste Management Updates

Recent updates

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 26

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Mar 23
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Feb 17
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11
TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18
We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Gavin MacBeath im Vergleich zu den Einnahmen von TScan Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$104m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$3mUS$545k

-US$89m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$1mUS$450k

-US$66m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$1mUS$400k

-US$49m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$533kUS$350k

-US$26m

Vergütung im Vergleich zum Markt: Gavin's total compensation ($USD3.20M) is above average for companies of similar size in the US market ($USD1.48M).

Entschädigung vs. Einkommen: Gavin's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Gavin MacBeath (54 yo)

1.7yrs

Amtszeit

US$3,196,054

Vergütung

Dr. Gavin MacBeath, Ph D., serves as CEO & Director of TScan Therapeutics, Inc. from May 24, 2023 and served as its Interim Principal Financial Officer since July 21, 2023 until 2023. Dr. MacBeath was Acti...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Gavin MacBeath
CEO & Director1.7yrsUS$3.20m0.094%
$ 246.4k
Zoran Zdraveski
Chief Legal & Strategy Officer and Company Secretary3.2yrsUS$1.58m0.0089%
$ 23.3k
Stephen Elledge
Co-Founder & Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
Tomasz Kula
Co-Founder & Member of Advisory Boardno datakeine Datenkeine Daten
Jason Amello
CFO & Treasurerless than a yearkeine Datenkeine Daten
Justin McCue
Chief Technology Officerless than a yearkeine Datenkeine Daten
Ann Hargraves
Senior Vice President of Human Resources4.8yrskeine Datenkeine Daten
Shrikanta Chattopadhyay
Senior VP & Head of Translational Medicine1.8yrskeine Datenkeine Daten
Ray Lockard
Senior Vice President & Head of Qualityless than a yearkeine Datenkeine Daten
Jim Murray
Senior VP & Head of Development Operationsless than a yearkeine Datenkeine Daten
Cagan Gurer
Senior Vice President of Discoveryless than a yearkeine Datenkeine Daten
Chrystal Louis
Chief Medical Officerless than a yearkeine Datenkeine Daten

0.9yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: TCRX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Gavin MacBeath
CEO & Director1.5yrsUS$3.20m0.094%
$ 246.4k
Stephen Elledge
Co-Founder & Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
Tomasz Kula
Co-Founder & Member of Advisory Boardno datakeine Datenkeine Daten
Malcolm Brenner
Member of Advisory Boardno datakeine Datenkeine Daten
Stephen Biggar
Independent Chair of the Board3.7yrsUS$123.17k0%
$ 0
Katina Dorton
Independent Director3.7yrsUS$132.59k0%
$ 0
Garry Nicholson
Directorless than a yearkeine Datenkeine Daten
Barbara Klencke
Director1.6yrsUS$121.74k0.13%
$ 346.5k
Kai Wucherpfennig
Member of Advisory Boardno datakeine Datenkeine Daten
Robert Woods
Independent Directorless than a yearUS$90.90kkeine Daten
Gabriela Gruia
Independent Director3.5yrsUS$113.53k0%
$ 0

1.6yrs

Durchschnittliche Betriebszugehörigkeit

66.5yo

Durchschnittliches Alter

Erfahrener Vorstand: TCRX's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.